Cancer Discov. 2016 Nov;6(11):OF4. doi: 10.1158/2159-8290.CD-NB2016-115. Epub 2016 Sep 14.
A phase III trial suggests that the combination of daratumumab, bortezomib, and dexamethasone is more powerful in patients with relapsed or relapsed and refractory melanoma than bortezomib plus dexamethasone. Patients who received all three drugs had a higher overall response rate and improved 12-month progression-free survival.
一项 III 期临床试验表明，与硼替佐米加地塞米松相比，达妥木单抗、硼替佐米和地塞米松联合用药对复发或复发及难治性黑色素瘤患者更有效。接受所有三种药物治疗的患者总体缓解率更高，12 个月无进展生存率得到改善。
